Stroke Risk in Patients With Reduced Ejection Fraction After Myocardial Infarction Without Atrial Fibrillation

التفاصيل البيبلوغرافية
العنوان: Stroke Risk in Patients With Reduced Ejection Fraction After Myocardial Infarction Without Atrial Fibrillation
المؤلفون: Kenneth Dickstein, Faiez Zannad, Marc A. Pfeffer, Bertram Pitt, Abhinav Sharma, John J.V. McMurray, João Pedro Ferreira, Azmil H. Abdul-Rahim, Nicolas Girerd, Patrick Rossignol, Ichraq Latar, John Gregson
المصدر: Journal of the American College of Cardiology. 71:727-735
بيانات النشر: Elsevier BV, 2018.
سنة النشر: 2018
مصطلحات موضوعية: Male, medicine.medical_specialty, Vasodilator Agents, 030204 cardiovascular system & hematology, Stroke risk, 03 medical and health sciences, 0302 clinical medicine, Risk Factors, Internal medicine, medicine, Humans, atrial fibrillation, In patient, cardiovascular diseases, Myocardial infarction, Stroke, Aged, Retrospective Studies, Ejection fraction, business.industry, food and beverages, Stroke Volume, Atrial fibrillation, Middle Aged, medicine.disease, stroke, myocardial infarction, cardiovascular system, Cardiology, Carvedilol, Female, Cardiology and Cardiovascular Medicine, business, 030217 neurology & neurosurgery, Follow-Up Studies
الوصف: Background:\ud Stroke can occur after myocardial infarction (MI) in the absence of atrial fibrillation (AF).\ud Objectives:\ud This study sought to identify risk factors (excluding AF) for the occurrence of stroke and to develop a calibrated and validated stroke risk score in patients with MI and heart failure (HF) and/or systolic dysfunction.\ud \ud Methods:\ud The datasets included in this pooling initiative were derived from 4 trials: CAPRICORN (Effect of Carvedilol on Outcome After Myocardial Infarction in Patients With Left Ventricular Dysfunction), OPTIMAAL (Optimal Trial in Myocardial Infarction With Angiotensin II Antagonist Losartan), VALIANT (Valsartan in Acute Myocardial Infarction Trial), and EPHESUS (Eplerenone Post–Acute Myocardial Infarction Heart Failure Efficacy and Survival Study); EPHESUS was used for external validation. A total of 22,904 patients without AF or oral anticoagulation were included in this analysis. The primary outcome was stroke, and death was treated as a “competing risk.”\ud \ud Results:\ud During a median follow-up of 1.9 years (interquartile range: 1.3 to 2.7 years), 660 (2.9%) patients had a stroke. These patients were older, more often female, smokers, and hypertensive; they had a higher Killip class; a lower estimated glomerular filtration rate; and a higher proportion of MI, HF, diabetes, and stroke histories. The final stroke risk model retained older age, Killip class 3 or 4, estimated glomerular filtration rate ≤45 ml/min/1.73 m2, hypertension history, and previous stroke. The models were well calibrated and showed moderate to good discrimination (C-index = 0.67). The observed 3-year event rates increased steeply for each sextile of the stroke risk score (1.8%, 2.9%, 4.1%, 5.6%, 8.3%, and 10.9%, respectively) and were in agreement with the expected event rates.\ud \ud Conclusions:\ud Readily accessible risk factors associated with the occurrence of stroke were identified and incorporated in an easy-to-use risk score. This score may help in the identification of patients with MI and HF and a high risk for stroke despite their not presenting with AF.
وصف الملف: application/pdf
تدمد: 0735-1097
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0bec8aa70bddab311ca4453932350c40
https://doi.org/10.1016/j.jacc.2017.12.011
حقوق: OPEN
رقم الأكسشن: edsair.doi.dedup.....0bec8aa70bddab311ca4453932350c40
قاعدة البيانات: OpenAIRE